Doravirine API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

 

Doravirine API Manufacturer & Bulk Supplier in India | Swapnroop Drugs & Pharmaceuticals

1. Introduction

Doravirine is a synthetic antiretroviral pharmaceutical ingredient belonging to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. It is used in combination with other antiretroviral medicines for the treatment of HIV-1 infection.

The drug works by inhibiting HIV-1 reverse transcriptase, an enzyme required for converting viral RNA into DNA. By interfering with this process, doravirine prevents an essential stage of viral replication.

Doravirine is a pyridinone-based NNRTI developed with activity against several HIV-1 strains, including certain strains carrying resistance-associated mutations to older NNRTIs. Its use depends on the patient's treatment history and the resistance profile of the virus.

In pharmaceutical manufacturing, doravirine is used as a defined chemical active pharmaceutical ingredient in oral tablet formulations. It is available as a single-ingredient product and in combination with lamivudine and tenofovir disoproxil fumarate.

For pharmaceutical manufacturers and procurement teams, important considerations include chemical identity, assay, related substances, stereochemical and structural integrity, solid-state characteristics, residual solvents, and batch-specific documentation.

Swapnroop Drugs & Pharmaceuticals welcomes pharmaceutical-sector product enquiries and sourcing discussions. Product availability, grade, specifications, and supporting documentation should be confirmed for each specific requirement.

2. What Is Doravirine API?

Doravirine is a second-generation non-nucleoside reverse transcriptase inhibitor developed to interfere with the activity of HIV-1 reverse transcriptase.

Unlike nucleoside reverse transcriptase inhibitors, which act as nucleotide analogues, doravirine binds to a separate allosteric site on the reverse transcriptase enzyme. This changes the enzyme's functional activity and prevents efficient viral DNA synthesis.

Doravirine is commonly recognised by its development code MK-1439 and its marketed brand name Pifeltro.

Key characteristics

  • Product name: Doravirine

  • Development code: MK-1439

  • CAS number: 1338225-97-0

  • Molecular formula: C₁₇H₁₁ClF₃N₅O₃

  • Molecular weight: Approximately 425.75 g/mol

  • Pharmacological class: Non-nucleoside reverse transcriptase inhibitor

  • Therapeutic category: Antiretroviral

  • Primary target: HIV-1 reverse transcriptase

  • Main application: Combination treatment of HIV-1 infection

  • Common dosage form: Film-coated oral tablets

Doravirine is a neutral small-molecule compound. The marketed Pifeltro product contains doravirine as its active ingredient, rather than a commonly used hydrochloride or sodium salt.

3. Doravirine API – Chemical Information

ParameterDetails
Product NameDoravirine
Generic NameDoravirine
Development CodeMK-1439
Brand NamePifeltro
CAS Number1338225-97-0
Molecular FormulaC₁₇H₁₁ClF₃N₅O₃
Molecular Weight425.75 g/mol
IUPAC Name3-Chloro-5-[[1-[(4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]benzonitrile
Chemical ClassPyridinone derivative
Pharmacological ClassNNRTI
Therapeutic AreaHIV treatment
AppearanceProduct-specific specification applies
Water SolubilityPractically insoluble in water

The molecular formula, molecular weight, and chemical identity are consistent with the PubChem record and the US prescribing information for Pifeltro.

4. Chemical Structure and Properties of Doravirine

Doravirine has a complex heterocyclic molecular structure containing a pyridinone ring system, a triazolone-containing side chain, a chlorinated aromatic group, and a trifluoromethyl substituent.

Its molecular structure contributes to its interaction with the allosteric binding pocket of HIV-1 reverse transcriptase.

Major structural characteristics

1. Pyridinone ring system

The pyridinone structure forms an important part of the molecular framework and contributes to the binding characteristics of doravirine.

2. Trifluoromethyl group

Doravirine contains a trifluoromethyl substituent. This fluorinated group influences the molecule's electronic and physicochemical properties.

3. Chlorinated aromatic group

The molecule contains a chlorine-substituted benzonitrile ring connected through an ether linkage.

4. Triazolone-containing side chain

The triazolone-containing portion of the molecule contributes to its heterocyclic structure and molecular recognition properties.

5. Nitrile functional group

The benzonitrile component is an important structural feature of doravirine.

Important physicochemical properties

  • Molecular weight: Approximately 425.75 g/mol

  • Molecular formula: C₁₇H₁₁ClF₃N₅O₃

  • Chemical type: Heterocyclic organic compound

  • Solubility in water: Practically insoluble

  • Functional groups: Pyridinone, triazolone, nitrile, ether, and fluorinated aromatic groups

The finished pharmaceutical formulation must account for the compound's limited aqueous solubility when selecting excipients and developing an appropriate oral dosage form.

5. Mechanism of Action of Doravirine

Doravirine inhibits HIV-1 reverse transcriptase through a mechanism known as non-competitive inhibition.

Reverse transcriptase is an essential viral enzyme that converts HIV RNA into DNA. This DNA can subsequently become integrated into the genetic material of the host cell.

Doravirine interferes with reverse transcriptase activity and reduces the production of viral DNA.

5.1 Binding to Reverse Transcriptase

Doravirine binds to an allosteric binding pocket on HIV-1 reverse transcriptase.

This binding site is distinct from the active site used by the enzyme to process nucleotide substrates.

5.2 Non-Competitive Enzyme Inhibition

By binding to the allosteric pocket, doravirine changes the functional activity of reverse transcriptase.

This interferes with the enzyme's ability to carry out RNA-dependent DNA polymerisation.

5.3 Inhibition of Viral DNA Synthesis

When reverse transcriptase activity is inhibited, the conversion of viral RNA into DNA is disrupted.

This reduces the production of viral DNA required for subsequent stages of HIV replication.

5.4 Selectivity for Viral Reverse Transcriptase

The FDA prescribing information reports that doravirine does not inhibit human cellular DNA polymerases alpha, beta, and mitochondrial DNA polymerase gamma in the cited biochemical evaluation.

Its activity is directed towards HIV-1 reverse transcriptase rather than these tested human polymerases.

5.5 Role in Combination Antiretroviral Therapy

Doravirine is used with other antiretroviral agents because combination therapy targets different stages of HIV replication.

Using appropriate combinations helps achieve viral suppression and reduces the likelihood of treatment failure associated with resistance.

6. Pharmaceutical Applications of Doravirine API

Doravirine has an established pharmaceutical application in HIV-1 treatment.

It is incorporated into oral antiretroviral products and combination medicines according to their respective regulatory approvals.

6.1 HIV-1 Treatment

Doravirine is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.

The US-approved Pifeltro product is indicated for adults and paediatric patients weighing at least 35 kg who meet the specified treatment-history and resistance criteria.

6.2 Antiretroviral Therapy in Treatment-Naive Patients

Doravirine-containing regimens may be used in eligible patients without prior antiretroviral treatment history.

The selection of a regimen depends on clinical evaluation, resistance considerations, other medicines being used, and the relevant treatment guidelines.

6.3 Treatment Switching in Virologically Suppressed Patients

The Pifeltro label also includes use in eligible patients who are already virologically suppressed on a stable antiretroviral regimen and meet the specified conditions.

These include having no history of treatment failure and no known substitutions associated with doravirine resistance.

6.4 Fixed-Dose Combination Products

Doravirine is available in a fixed-dose combination with lamivudine and tenofovir disoproxil fumarate.

This combination provides three antiretroviral agents with complementary mechanisms of action.

6.5 Pharmaceutical Research and Development

Doravirine is relevant to pharmaceutical research involving:

  • HIV reverse transcriptase inhibition

  • NNRTI drug development

  • Antiviral formulation development

  • Drug-excipient compatibility

  • Analytical method development

  • Related-substance evaluation

  • Solid-state characterisation

7. Common Pharmaceutical Formulations Containing Doravirine

Doravirine is formulated primarily as an oral solid dosage form.

Dosage FormExampleGeneral Application
Film-Coated TabletsPifeltroOral antiretroviral treatment
Fixed-Dose Combination TabletsDelstrigoCombination HIV treatment

7.1 Pifeltro

Pifeltro is a single-ingredient film-coated tablet containing 100 mg of doravirine.

The US prescribing information describes the product as an oral tablet used in combination with other antiretroviral medicines.

7.2 Delstrigo

Delstrigo is a fixed-dose combination product containing:

  • Doravirine: 100 mg

  • Lamivudine: 300 mg

  • Tenofovir disoproxil fumarate: 300 mg

The three ingredients act through different mechanisms involved in the HIV replication cycle.

These strengths describe the specific marketed formulation and should not be treated as universal requirements for every product or market.

8. Doravirine in Fixed-Dose Combination Products

Fixed-dose combinations are important in antiretroviral treatment because they bring multiple active ingredients into one pharmaceutical dosage form.

Doravirine is combined with lamivudine and tenofovir disoproxil fumarate in Delstrigo.

8.1 Doravirine

Doravirine inhibits HIV-1 reverse transcriptase through non-competitive allosteric inhibition.

8.2 Lamivudine

Lamivudine is a nucleoside reverse transcriptase inhibitor. It interferes with viral DNA synthesis through a mechanism different from doravirine.

8.3 Tenofovir Disoproxil Fumarate

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor prodrug. Following conversion to its active form, it interferes with HIV reverse transcriptase activity.

8.4 Formulation Development Considerations

Manufacturers developing fixed-dose combination products should evaluate:

  • API identity and purity

  • Compatibility between active ingredients

  • Excipient compatibility

  • Blend uniformity

  • Content uniformity

  • Dissolution characteristics

  • Chemical and physical stability

  • Moisture sensitivity

  • Packaging compatibility

  • Regulatory requirements

Each combination product requires an independent formulation and quality-control strategy.

9. Manufacturing and Processing Considerations

Doravirine is a synthetic small-molecule pharmaceutical ingredient. Its manufacturing involves controlled chemical synthesis, purification, isolation, and final quality evaluation.

The precise manufacturing route and process conditions depend on the validated manufacturing process.

9.1 Starting Material Qualification

Starting materials should be evaluated before entering the manufacturing process.

Important considerations include:

  • Chemical identity

  • Purity

  • Related impurities

  • Supplier qualification

  • Batch traceability

  • Compliance with the approved specification

9.2 Chemical Synthesis

The synthesis involves controlled chemical transformations to construct the doravirine molecular framework.

The process must be designed to maintain the required chemical identity and control unwanted reaction-related impurities.

9.3 Intermediate Control

Intermediate materials should be evaluated at appropriate manufacturing stages.

Relevant controls may include identity, assay, impurity profile, and other process-specific quality parameters.

9.4 Purification

Purification operations remove residual starting materials, intermediates, and process-related impurities.

Suitable purification controls are important for achieving the required final API quality.

9.5 Crystallisation and Isolation

Crystallisation and isolation operations produce the final solid material.

Process conditions can influence particle characteristics, crystalline properties, and batch consistency.

9.6 Drying and Packaging

Drying and packaging should be performed under controlled conditions to maintain material quality and prevent contamination.

The packaging system should protect the API during storage and transportation.

Note: This is a general pharmaceutical manufacturing overview, not a validated manufacturing procedure or a claim regarding SDP's manufacturing capabilities.

10. Quality Control and Testing of Doravirine API

Quality control is essential for ensuring that doravirine meets its applicable pharmaceutical specification.

Testing should evaluate chemical identity, assay, impurity profile, physical properties, and other relevant quality attributes.

10.1 Identification Testing

Identification testing confirms that the material corresponds to doravirine.

Possible analytical approaches include:

  • Infrared spectroscopy

  • HPLC identification

  • Mass spectrometry

  • Other applicable validated procedures

10.2 Assay Testing

Assay testing determines the quantity of doravirine present in the material.

The analytical method and acceptance criteria should follow the applicable current pharmacopoeial monograph, approved specification, or customer-approved quality standard.

10.3 Related Substances

Related-substance testing evaluates impurities introduced during synthesis, purification, or storage.

Chromatographic techniques are commonly used to separate and quantify relevant impurities.

10.4 Residual Solvents

Residual solvent testing evaluates solvents that may remain following chemical synthesis and purification.

The requirements should follow the applicable specification and relevant ICH Q3C guidance.

10.5 Water Content

Water-content testing helps evaluate the material's quality and suitability for pharmaceutical processing.

A suitable analytical method should be selected according to the approved specification.

10.6 Solid-State Characterisation

Solid-state characterisation may be relevant to the evaluation of crystalline form, particle properties, and physical consistency.

Possible techniques include:

  • Powder X-ray diffraction

  • Differential scanning calorimetry

  • Thermogravimetric analysis

  • Particle-size analysis, where required

10.7 Packaging Integrity

Packaging should be evaluated for correct closure, labelling, batch traceability, and protection against contamination.

11. Analytical Methods Used for Doravirine API

Several analytical methods may be used to evaluate doravirine.

Analytical MethodPurpose
HPLCAssay and related-substances analysis
FTIR SpectroscopyChemical identification
LC-MSMolecular identity and impurity characterisation
UV-Visible SpectroscopySelected quantitative analytical applications
Karl Fischer TitrationWater-content determination
Gas ChromatographyResidual solvent analysis
Powder X-ray DiffractionCrystalline-form evaluation
DSCThermal characterisation
TGAThermal and volatile-content assessment

The final analytical programme should be based on the current applicable specification, validated methods, and intended pharmaceutical application.

12. Storage and Handling of Doravirine API

Proper storage and handling are important for maintaining the quality and integrity of doravirine.

The API's approved storage conditions should be established using its own specification and supporting stability data.

Storage considerations

  • Store in suitable, well-closed containers.

  • Protect the material from contamination.

  • Follow the approved storage conditions.

  • Maintain appropriate warehouse controls.

  • Avoid unnecessary exposure to unsuitable environmental conditions.

  • Follow supplier packaging recommendations.

  • Maintain batch identification and traceability.

Handling precautions

Personnel handling doravirine should:

  • Consult the current Safety Data Sheet.

  • Use suitable protective gloves.

  • Wear appropriate eye protection.

  • Avoid unnecessary dust generation.

  • Prevent accidental ingestion and direct exposure.

  • Follow workplace hygiene procedures.

  • Use approved sampling and dispensing controls.

The storage conditions for the bulk API should not automatically be assumed to be identical to those of the finished Pifeltro or Delstrigo products.

13. Safety and Regulatory Considerations

Doravirine is a prescription antiretroviral medicine. Its development and use are governed by product-specific prescribing information and applicable national regulations.

13.1 Severe Skin Reactions

The current US prescribing information reports severe skin reactions, including:

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Drug rash with eosinophilia and systemic symptoms (DRESS)

These reactions require appropriate clinical assessment and management.

13.2 Drug Interactions

Doravirine exposure can be significantly reduced by strong CYP3A enzyme inducers.

The US prescribing information identifies examples including:

  • Rifampin

  • Rifapentine

  • Carbamazepine

  • Oxcarbazepine

  • Phenobarbital

  • Phenytoin

  • Enzalutamide

  • Mitotane

  • St. John's wort

Such interactions can reduce doravirine concentrations and potentially compromise antiviral effectiveness.

13.3 Immune Reconstitution Inflammatory Syndrome

Immune reconstitution syndrome has been reported during combination antiretroviral treatment.

It may occur when the immune system begins to recover and responds to previously existing or residual infections.

13.4 Resistance Considerations

As with other antiretroviral medicines, HIV can develop resistance-associated mutations.

Treatment selection should consider relevant resistance information and the patient's antiretroviral history.

13.5 Regulatory Considerations for Manufacturers

Pharmaceutical manufacturers should evaluate:

  • Applicable GMP requirements

  • API identity and purity

  • Related-substance controls

  • Residual solvent requirements

  • Stability data

  • Validated analytical methods

  • Packaging qualification

  • Batch traceability

  • Regulatory filing requirements

  • Change-control procedures

The applicable regulatory requirements vary according to the intended market and product type.

14. Doravirine Compared with Other NNRTIs

Doravirine belongs to the non-nucleoside reverse transcriptase inhibitor class. Other medicines in this class include efavirenz, nevirapine, rilpivirine, and etravirine.

These medicines share a general therapeutic target but differ in chemical structure, pharmacological properties, resistance profiles, and clinical use.

DrugTherapeutic ClassGeneral Description
DoravirineNNRTIPyridinone-based HIV-1 reverse transcriptase inhibitor
EfavirenzNNRTIEarlier-generation antiretroviral medicine
NevirapineNNRTIHIV reverse transcriptase inhibitor
RilpivirineNNRTIDiarylpyrimidine-based antiretroviral
EtravirineNNRTIAntiretroviral with activity against selected NNRTI-resistant HIV strains

These active ingredients are not automatically interchangeable. Their selection and use must follow the relevant treatment guidelines, product approvals, and resistance considerations.

15. Pharmaceutical Procurement Considerations

Pharmaceutical manufacturers and procurement teams sourcing doravirine should evaluate product identity, quality, documentation, and regulatory suitability.

15.1 Confirm Chemical Identity

Verify that the required material is doravirine, CAS 1338225-97-0.

15.2 Confirm the Required Grade

Identify the intended pharmaceutical grade and applicable customer or pharmacopoeial specification.

15.3 Review the Certificate of Analysis

A batch-specific Certificate of Analysis should include actual test results, analytical methods, and acceptance criteria.

15.4 Evaluate Related Substances

Review the impurity profile and confirm that relevant impurities are controlled using suitable analytical methods.

15.5 Review Residual Solvents

Evaluate residual solvent results according to the manufacturing process and applicable regulatory requirements.

15.6 Assess Physical Characteristics

Where required, review solid-state characteristics, particle properties, and other physical parameters relevant to formulation development.

15.7 Verify Supplier Documentation

Depending on the intended application, buyers may request:

  • Batch-specific Certificate of Analysis

  • Product specification

  • Safety Data Sheet

  • Manufacturing and testing information

  • Stability data

  • Relevant compliance declarations

  • Packaging details

15.8 Confirm Destination-Market Requirements

Verify the relevant regulatory requirements, documentation, labelling, and transportation conditions before procurement.

16. Doravirine API Market and Pharmaceutical Industry Relevance

Doravirine is an important antiretroviral ingredient because of its role in NNRTI-based HIV treatment regimens.

Its availability as a single-ingredient product and as part of a fixed-dose combination makes it relevant to pharmaceutical manufacturers involved in HIV treatment products.

Important industry considerations include:

  • Consistent chemical quality

  • Reliable API identification

  • Controlled related substances

  • Residual solvent management

  • Validated analytical testing

  • Solid-state characterisation

  • Formulation compatibility

  • Stability assessment

  • Regulatory compliance

  • Complete batch documentation

For pharmaceutical procurement teams, selecting an appropriate API requires attention to both chemical quality and the regulatory requirements of the destination market.

17. Doravirine API Enquiries – Swapnroop Drugs & Pharmaceuticals

Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, formulation developers, distributors, and procurement professionals.

For a Doravirine API enquiry, buyers should specify:

  • Product name: Doravirine

  • CAS number: 1338225-97-0

  • Molecular formula: C₁₇H₁₁ClF₃N₅O₃

  • Molecular weight: 425.75 g/mol

  • Required pharmaceutical grade

  • Applicable quality specification

  • Required quantity

  • Intended formulation

  • Documentation requirements

  • Destination market

Product identity, grade, availability, supporting documentation, and commercial terms should be confirmed directly before any purchase commitment.

Contact Swapnroop Drugs & Pharmaceuticals for product-related business enquiries and sourcing discussions.

18. Frequently Asked Questions (FAQs)

Q1. What is Doravirine API?

Doravirine is a synthetic antiretroviral pharmaceutical ingredient belonging to the non-nucleoside reverse transcriptase inhibitor class. It is used in combination with other medicines for the treatment of HIV-1 infection.

Q2. What is the CAS number of Doravirine?

The CAS number of doravirine is 1338225-97-0.

Q3. What is the molecular formula of Doravirine?

The molecular formula is C₁₇H₁₁ClF₃N₅O₃.

Q4. What is the molecular weight of Doravirine?

The molecular weight of doravirine is approximately 425.75 g/mol.

Q5. What is the brand name of Doravirine?

Pifeltro is a marketed single-ingredient product containing doravirine. Delstrigo is a fixed-dose combination containing doravirine, lamivudine, and tenofovir disoproxil fumarate.

Q6. How does Doravirine work?

Doravirine inhibits HIV-1 reverse transcriptase through non-competitive inhibition. It binds to an allosteric site on the enzyme and interferes with viral DNA synthesis.

Q7. What is the pharmaceutical application of Doravirine?

Doravirine is used in combination with other antiretroviral medicines for the treatment of HIV-1 infection in eligible patients.

Q8. Is Doravirine an NNRTI?

Yes. Doravirine belongs to the non-nucleoside reverse transcriptase inhibitor class.

Q9. Is Doravirine available in combination products?

Yes. Doravirine is included in Delstrigo, a fixed-dose combination with lamivudine and tenofovir disoproxil fumarate.

Q10. What quality tests are important for Doravirine API?

Important tests include identification, assay, related substances, residual solvents, water content, and physical or solid-state characterisation where required.

Q11. What are important regulatory considerations for Doravirine?

Manufacturers should evaluate GMP requirements, API quality, analytical validation, impurity controls, stability, regulatory documentation, and destination-market requirements.

Q12. What documents should buyers review when sourcing Doravirine API?

Buyers should review a batch-specific Certificate of Analysis, product specification, Safety Data Sheet, manufacturing and testing information, stability data, and relevant compliance documentation.

Conclusion

Doravirine is a pyridinone-based non-nucleoside reverse transcriptase inhibitor used in combination antiretroviral therapy for HIV-1 infection. Its mechanism involves non-competitive inhibition of HIV-1 reverse transcriptase, which interrupts viral DNA synthesis.

With a molecular formula of C₁₇H₁₁ClF₃N₅O₃, a molecular weight of approximately 425.75 g/mol, and CAS number 1338225-97-0, doravirine is a specialised small-molecule API used in oral antiretroviral products.

For pharmaceutical manufacturers, important quality considerations include chemical identity, assay, related substances, residual solvents, solid-state characteristics, stability, and batch documentation.

Swapnroop Drugs & Pharmaceuticals welcomes product-related business enquiries from pharmaceutical manufacturers, distributors, and procurement professionals. Product grade, availability, documentation, and commercial details should be verified before procurement.

Comments

Popular posts from this blog

🌿 Probiotics IR Pellets – Fast-Acting Gut Health Solution by Swapnroop Drugs & Pharmaceuticals 🌿

🌱 Probiotics EC Pellets – Stabilized Gut Health Powerhouses by Swapnroop Drugs & Pharmaceuticals

Azithromycin Taste-Masked Powder: A Pediatric-Friendly Innovation by Swapnroop Drugs & Pharmaceuticals